Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Arcellx Inc (ACLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ACLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 35.42% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.52B USD | Price to earnings Ratio - | 1Y Target Price 115.4 |
Price to earnings Ratio - | 1Y Target Price 115.4 | ||
Volume (30-day avg) 709916 | Beta 0.33 | 52 Weeks Range 47.88 - 107.37 | Updated Date 04/26/2025 |
52 Weeks Range 47.88 - 107.37 | Updated Date 04/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -99.46% | Operating Margin (TTM) -348.17% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -22.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2975386271 | Price to Sales(TTM) 32.64 |
Enterprise Value 2975386271 | Price to Sales(TTM) 32.64 | ||
Enterprise Value to Revenue 27.57 | Enterprise Value to EBITDA -6.52 | Shares Outstanding 55072700 | Shares Floating 32601579 |
Shares Outstanding 55072700 | Shares Floating 32601579 | ||
Percent Insiders 2.32 | Percent Institutions 110.05 |
Analyst Ratings
Rating 4.68 | Target Price 116.38 | Buy 6 | Strong Buy 13 |
Buy 6 | Strong Buy 13 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arcellx Inc
Company Overview
History and Background
Arcellx, Inc. is a clinical-stage biotechnology company founded in 2015. It focuses on developing adaptive and controllable cell therapies for patients with cancer and other incurable diseases. The company has advanced clinical programs targeting multiple myeloma.
Core Business Areas
- ARC-SP1: Arcellx's lead product candidate, ARC-SP1, is a BCMA-targeting CAR-T therapy for relapsed or refractory multiple myeloma. It utilizes the company's D-Domain technology to enhance control and improve safety.
Leadership and Structure
Arcellx is led by a management team with experience in cell therapy development and commercialization. The company has a board of directors comprising industry veterans.
Top Products and Market Share
Key Offerings
- ARC-SP1: ARC-SP1 is Arcellx's lead CAR-T therapy candidate for multiple myeloma. It is in clinical development and does not yet have market share or revenue. Competitors include BMS (Abecma) and Johnson & Johnson (Carvykti).
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing field, driven by advances in immunotherapy and personalized medicine. Multiple myeloma is a large and unmet medical need.
Positioning
Arcellx aims to differentiate itself through its D-Domain technology, which allows for enhanced control and safety of CAR-T therapies. They are positioned to compete in the multiple myeloma CAR-T therapy market.
Total Addressable Market (TAM)
The total addressable market for multiple myeloma therapies is significant, estimated to be in the billions of dollars annually. Arcellx aims to capture a portion of this market with ARC-SP1.
Upturn SWOT Analysis
Strengths
- Innovative D-Domain technology
- Strong preclinical and clinical data for ARC-SP1
- Experienced management team
- Potential for improved safety and efficacy compared to existing CAR-T therapies
Weaknesses
- Clinical stage company with no approved products
- Dependence on the success of ARC-SP1
- High cost of cell therapy development and manufacturing
- Limited commercial infrastructure
Opportunities
- Growing market for cell therapies
- Potential to expand D-Domain technology to other indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results could accelerate regulatory approval
Threats
- Competition from established CAR-T therapies
- Regulatory hurdles
- Manufacturing challenges
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- MRTX
Competitive Landscape
Arcellx faces competition from established pharmaceutical companies with approved CAR-T therapies, as well as other biotechnology companies developing novel cell therapies. Its D-Domain technology is a key differentiator.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Arcellx's historical growth has been focused on advancing its pipeline of cell therapy candidates.
Future Projections: Future growth is dependent on the success of ARC-SP1 and other pipeline candidates. Analyst estimates vary.
Recent Initiatives: Arcellx is focused on completing clinical trials for ARC-SP1, expanding its manufacturing capabilities, and exploring new applications of its D-Domain technology.
Summary
Arcellx is a clinical-stage biotech company with promising D-Domain technology, particularly in its ARC-SP1 CAR-T therapy for multiple myeloma. The company's success hinges on positive clinical trial outcomes and successful commercialization. Competition from established players and regulatory hurdles pose significant challenges. While ARC-SP1 is not yet approved the company has potential to have a great future.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Arcellx Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is an estimate based on publicly available information. Future results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcellx Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2022-02-04 | Chairman of the Board, CEO & President Mr. Rami Elghandour | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.arcellx.com |
Full time employees 163 | Website https://www.arcellx.com | ||
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.